Overview
- In April a senior NIH clinician filed an expanded‑access request that resulted in a single 79‑year‑old patient receiving retatrutide, Eli Lilly’s investigational obesity drug.
- The White House has denied that President Trump was the recipient while the patient’s identity remains undisclosed to reporters.
- Sen. Maggie Hassan sent a letter to HHS Secretary Robert F. Kennedy Jr. and Rep. Ted Lieu publicly pressed the White House for records and explanations about who approved the access and whether the drug was provided free.
- Medical ethicists and clinicians say one‑patient compassionate use for an obesity indication is unusual given existing approved treatments and raise questions about the medical basis for the exception.
- The story could prompt formal congressional oversight of HHS, the FDA, and Eli Lilly and the public should watch for agency records and responses that explain the decision process and any communications with the White House.